December 15, 2025 -- Imunopharm Technology Co., Ltd. (hereinafter referred to as "Imunopharm" or "the Company") officially announced the appointment of Ms. Jane Fu as Vice President of Business. She will be fully responsible for the strategic planning and management of the Commercialization and Business Development Department, reporting directly to Dr. Lu Xin'an, Co-founder of the Company.
Ms. Fu will take the lead in developing and executing the Company’s commercialization strategies, overseeing go-to-market frameworks of post-launch products, end-to-end commercial capabilities build up , strategic partnership management, and be responsible for the sales performance achievement. Aligned with the Company’s overall development strategy, she will drive efficient collaboration between the commercial team, R&D and manufacturing divisions. Meanwhile, she will focus on both domestic and overseas markets to build a sustainable commercial profit model, providing a core driving force for the business growth.
Ms. Fu holds a Bachelor of Science degree in Biology from Tsinghua University, and a joint Master’s degree in Bioscience Enterprise from the Institute of Biotechnology and Judge Business School, University of Cambridge where she was awarded a full scholarship by Cambridge Trust. Prior to joining Imunopharm, she served in senior roles at leading biopharmaceutical companies, including Head of Marketing, Gastroenterology & Immunology Business Unit at Takeda, Disease Area Lead for Asia Pacific at Johnson & Johnson, Head of Government Affairs & Market Access Strategy at Johnson & Johnson, and Head of New Products at Novartis.
With extensive experience in high-value therapeutic areas including oncology, vaccines, immunology and ophthalmology, Ms. Fu has profound practical expertise and industry influence in cell and gene therapy (CGT), innovative payment models, and cross-enterprise commercial cooperation. She has spearheaded multiple groundbreaking industry projects, led cross-regional teams to achieve leapfrog business growth, and continuously strengthened brands'market leadership, demonstrating exceptional capabilities in strategic planning, organizational collaboration and global resource integration.
Ms. Jane Fu commented: "I am honored to join Imunopharm, an innovative force deeply committed to the field of cell and gene therapy. As a revolutionary technology with genuine curative potential, CGT breaks through the therapeutic ceiling that has long constrained traditional therapies and brings renewed hope to countless patients — this is the core passion that drives me to engage in this track. Leveraging my comprehensive end-to-end commercialization experience, I will prioritize patient access as the central tenet, develop go-to-market strategies, build out robust commercial capabilities and strengthen stratgic partnership collaborations. I will also facilitate seamless synergy between commercialization, R&D and manufacturing functions, and help the Company achieve a win-win outcome of commercial value and patient well-being."
Dr. He Ting, CEO of Imunopharm, stated: "We warmly welcome Ms. Fu to join our team. Ms. Fu’s profound commercial background and outstanding leadership in the biopharmaceutical industry will bring valuable strategic insights and practical experience to the Company. Her appointment marks a critical step forward in Imunopharm’s commercial capability building, and will further accelerate our transformation process from R&D innovation to market value realization. I am confident that under her leadership, our commercial team will operate with greater efficiency and synergy, jointly propelling Imunopharm to become a significant player in the global innovative pharmaceutical landscape."
